News | Wearables | October 31, 2019

AliveCor and Huami Partner for Next Generation Medical Wearables

AliveCor's KardiaMobile six-lead ECG system that works on smartphone platforms. It was cleared in 2019 and includes artificial intelligence algorithms to help identify arrhythmias.

AliveCor's KardiaMobile six-lead ECG system that works on smartphone platforms. It was cleared in 2019 and includes artificial intelligence algorithms to help identify arrhythmias. 

October 31, 2019 — AliveCor, a provider of smartphone based ECG technology and Huami Corp., a provider of biometric, data-driven wearables, announced a global strategic alliance that combines the technologies of each company to deliver a new generation of medical functionality to wearable devices.

“AliveCor’s intelligent, medical grade, heart care platform will be a key component of Huami smart watches and heart trackers going forward. Our new partnership is critical to building these as well as entirely new medical grade services,” said Wang Huang, CEO of Huami.

“AliveCor’s agreement with Huami achieves our corporate goal of delivering AliveCor’s artificial intelligence (AI) driven subscription services and solutions to enterprise customers and consumers worldwide at affordable price points. AliveCor technology allows partners to easily deliver clinically validated, peer-reviewed medical features to their own customers, at scale,” said AliveCor CEO Priya Abani.

The agreement announced today encompasses the licensing of AliveCor technology and an agreement to work together to bring new devices and services to market. The companies expect that the alliance will deliver entirely new ECG form factors to global markets in 2020.

Huami began operations in 2013 and quickly grew, shipping millions of units of smart wearable devices. In 2018, Huami shipped 27.5 million units of smart wearable devices. Huami has one of the largest biometric and activity databases in the global smart wearables industry. Huami’s mobile apps work hand in hand with its smart wearable devices and provide users with a comprehensive view and analysis of their biometric and activity data.

AliveCor offers cardiological care in smartphone based apps that use deep learning. The FDA-cleared KardiaMobile is the most clinically validated personal ECG solution in the world. KardiaMobile provides instant detection of atrial fibrillation, bradycardia, tachycardia, and normal rhythm in an ECG. Kardia is the first AI enabled platform to aid patients and clinicians in the early detection of atrial fibrillation, the most common arrhythmia and one associated with a five times greater risk of stroke. AliveCor’s KardiaPro enterprise platform allows practitioners and institutions to manage chronic heart conditions simply and profitably using KardiaMobile. 

For more information: alivecor.com

Related Content

With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a costly tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. Amyloidosis Patient Registry  #Amyloidosis

With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. This is Figure 2, showing how SPECT imaging allows the reader to distinguish between blood pool activity (ventricular cavity, etc) and myocardial activity and identify regional myocardial differences in radiotracer uptake.

News | Cardiac Diagnostics | March 05, 2020
March 5, 2020 — More than 300 patients have joined the Amyloidosis Patient Registry and it is now available to the en
heart disease image
News | Cardiac Diagnostics | December 18, 2019
December 18, 2019 — In their latest report, “...
FDA Warns Troponin Tests Impacted by Biotin Dietary Supplement
Feature | Cardiac Diagnostics | November 05, 2019 | Dave Fornell, Editor
November 5, 2019 — The U.S.
Videos | Cardiac Diagnostics | October 29, 2019
Doctor Clyde Yancy was a keynote speaker and said doctors need to check their assumptions about patients at the door...
79-year-old Tony Marovic had a right carotid endarterectomy shortly after discovering a 95 percent blockage of his carotid artery at a health and wellness screening event

79-year-old Tony Marovic had a right carotid endarterectomy shortly after discovering a 95 percent blockage of his carotid artery at a health and wellness screening event. Image courtesy of University Hospitals.

News | Cardiac Diagnostics | October 16, 2019
Health and wellness screenings are more than just nice events for the community – they can save lives. A Mentor, Ohio,...
Pesticide Exposure May Increase Heart Disease and Stroke Risk

Image courtesy of zefe wu from Pixabay

News | Cardiac Diagnostics | October 15, 2019
On-the-job exposure to high levels of pesticides raised the risk of heart disease and stroke in a generally healthy...
World Heart Federation Launches Global Roadmap on Cardiovascular Disease Prevention Among Diabetics
News | Cardiac Diagnostics | September 04, 2019
At the European Society of Cardiology (ESC) Congress 2019 together with the World Congress of Cardiology, the World...
Insomnia Tied to Higher Risk of Heart Disease and Stroke

Image courtesy of the American Heart Association

News | Cardiac Diagnostics | August 19, 2019
People suffering from insomnia may have an increased risk of coronary artery disease, heart failure and stroke,...